Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 10;4(1):e241.
doi: 10.1002/hsr2.241. eCollection 2021 Mar.

Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high-risk populations: A systematic review and meta-analysis

So-Jung Shim  1 , Mei Chan  1   2 , Louisa Owens  1   2 , Adam Jaffe  1   2 , Bernadette Prentice  1   2 , Nusrat Homaira  1   2
Affiliations

Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high-risk populations: A systematic review and meta-analysis

So-Jung Shim et al. Health Sci Rep. .

Abstract

Background: Oseltamivir is recommended in the treatment of influenza illness in high-risk populations, including those with chronic heart and lung diseases.

Objectives: We conducted a systematic review and meta-analysis to determine the rate of use and effectiveness of oseltamivir in these groups of patients.

Methods: The protocol for the systematic review was registered on PROSPERO (CRD42019125998). Medline, EMBASE, Cochrane CENTRAL, and CINAHL were searched for observational studies and randomized controlled trials published up to 16 February 2020. Quality appraisal of final studies was conducted using GRADE guidelines. Data were extracted using a predeveloped template. Main outcomes measured included the rate of use of oseltamivir for influenza-like-illness and its effectiveness in reducing disease severity in patients with cardiopulmonary diseases. Outcomes measured for effectiveness were influenza-related complications (respiratory infections and asthma exacerbations), hospitalization rates, and time to freedom from illness. Risk of bias was assessed using Cochrane's Risk of Bias 2.0 tool for randomized trials and Cochrane's Risk of Bias in nonrandomized Studies of Interventions tool for nonrandomized trials. Where data were available, pooled analyses were conducted. Dichotomous variables were evaluated using the Mantel-Hansel method. A random effect model was applied. Summary measures were reported as risk ratios where relevant.

Results: Our systematic review identified nine studies. Oseltamivir use ranged from 25% to 100%. When oseltamivir group was compared to placebo, rates of respiratory tract infections reduced by 28% (RR = 0.72, 95% CI = 0.59-0.90), hospitalization reduced by 52% (RR = 0.48, 95% CI = 0.28-0.80) and median time to illness alleviation decreased by 10.4 to 120 hours. There was no significant reduction in asthma exacerbation rates.

Conclusions: Our systematic review suggests that the use of oseltamivir is beneficial in reducing disease severity, however, its use in high-risk population remains suboptimal.

Keywords: heart diseases; human; influenza; lung diseases; oseltamivir.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

FIGURE 1
FIGURE 1
Study selection flowchart based on preferred reporting items for systematic reviews and meta‐analyses (PRISMA) 24
FIGURE 2
FIGURE 2
Forest plots comparing effectiveness of oseltamivir in reducing rates of, A, hospitalization, B, respiratory complications, C, asthma exacerbations in people with cardiopulmonary disease who were prescribed oseltamivir compared to those who were not
FIGURE 3
FIGURE 3
Effectiveness of oseltamivir in reducing, A, time to alleviation of illness (hours), b, severity of illness in people with cardiopulmonary disease who were prescribed oseltamivir compared to those who were not
FIGURE A1
FIGURE A1
Risk of bias in randomised trials measuring effectiveness of oseltamivir (based on Cochrane RoB 2.0 tool)
FIGURE A2
FIGURE A2
Risk of bias in nonrandomized studies measuring the rate of use of oseltamivir (based on ROBINS‐I tool)
FIGURE A3
FIGURE A3
Funnel plots for: A, Rates of hospitalization, B, Rates of asthma exacerbation, C, Rates of respiratory complications, D, Severity of illness
See this image and copyright information in PMC

References

    1. WHO . Ask the expert: Influenza Q&A; 2018. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
    1. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza‐associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285‐1300. - PMC - PubMed
    1. WHO . WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. 2010. - PubMed
    1. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta‐analysis. Lancet. 2011;378(9807):1917‐1930. - PubMed
    1. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta‐analysis. BMJ. 2013;347:f5061. - PMC - PubMed

LinkOut - more resources